Bayer’s Stivarga approved for second-line liver cancer treatment

Bayer has announced that its cancer drug Stivarga has been approved in a new liver cancer indication by the European Commission.

The regulator has granted marketing authorisation for Stivarga for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with Nexavar.

Stivarga is the first and only treatment that has demonstrated a significant improvement in overall survival in the second-line treatment of this condition, showing a strong performance in the phase III RESORCE study.

This approval represents the first major treatment advance for patients with this form of liver cancer in nearly a decade.

Robert LaCaze, executive vice-president and head of the oncology strategic business unit at Bayer, said: "Bayer continues to support the liver cancer community and is committed to ongoing research in the field, as well as continuing to pursue additional regulatory filings for Stivarga across the world."

This marks the third major approval in five months for Stivarga, with the product also having been approved in the US and Japan for second-line treatment of hepatocellular carcinoma in April and June.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.